HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...

10月15日，辉瑞制药宣布，HYMPAVZI ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

10月15日，辉瑞制药宣布，HYMPAVZI™（马塔西单抗/marstacimab-hncq）近日获美国食品药品监督管理局（FDA）批准，用于规律性治疗不伴凝血因子抑制物的血友病A（先天性凝血VIII因子缺乏症）或血友病B（先天性凝血IX因子缺乏症）的12岁以上患者，以减少出血的发作。HYMPAVZI是辉瑞今年获得FDA批准的第二款血友病治疗药物。

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

The FDA granted the approval of Hympavzi to Pfizer Inc.

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...

Pfizer (NYSE:PFE) said the FDA has approved its drug Hympavzi for the treatment of certain types of hemophilia. The agency ...

10月15日，辉瑞官微发布消息称，期创新药物HYMPAVZI™（马塔西单抗/marstacimab-hncq）获美国食品药品监督管理局（FDA）批准，用于规律性治疗不伴凝血因子抑制物的血友病A（先天性凝血VIII因子缺乏症）或血友病 ...

The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...